Inhibition of VEGF, one of the key mediators of angiogenesis, by molecular-targeting agent may, therefore, be an important approach towards development of potential anticancer therapy for regressing NSCLC. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.